相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Advanced Prostate Cancer: Treatment Advances and Future Directions
Umang Swami et al.
TRENDS IN CANCER (2020)
Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer
Hideaki Miyake et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2019)
Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer
Toshiki Ito et al.
ANTICANCER RESEARCH (2019)
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Kim N. Chi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer
Hideaki Miyake et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2018)
Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan
Hideaki Miyake et al.
CLINICAL GENITOURINARY CANCER (2018)
No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer
Hideaki Miyake et al.
MEDICAL ONCOLOGY (2017)
Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide
Hideaki Miyake et al.
MEDICAL ONCOLOGY (2017)
Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Hideaki Miyake et al.
CLINICAL GENITOURINARY CANCER (2017)
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone
Dana E. Rathkopf et al.
CLINICAL CANCER RESEARCH (2017)
Comparative Assessment of Clinical Outcomes Between Abiraterone Acetate and Enzalutamide in Patients With Docetaxel-Naive Metastatic Castration-Resistant Prostate Cancer: Experience in Real-World Clinical Practice in Japan
Hideaki Miyake et al.
CLINICAL GENITOURINARY CANCER (2017)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Clinical outcomes of anti-androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial maximum androgen blockade
Hiroyuki Momozono et al.
MOLECULAR AND CLINICAL ONCOLOGY (2016)
分享论文
